Certain Ordinary Shares of Cutia Therapeutics are subject to a Lock-Up Agreement Ending on 11-DEC-2023. These Ordinary Shares will be under lockup for 185 days starting from 9-JUN-2023 to 11-DEC-2023.

Details:
The Controlling Shareholders of the company, 6 Dimensions Capital, L.P. (61,771,710 shares), 6 Dimensions Affiliates Fund, L.P. (3,251,145 shares), Suzhou 6 Dimensions Venture Capital Partnership L.P. (60,516,000 shares), Suzhou Frontline BioVentures Venture Capital Fund II L.P. (25,935,425 shares), have agreed for the lock-up of first six month period ending on December 11, 2023 and the second six month period ending on June 11, 2024.

Other Existing Shareholders, YF Dermatology Limited (40,000,000 shares), SCC Growth V 2020-C, L.P. (34,285,715 shares), Cormorant Private Healthcare Fund II, LP (4,523,430 shares), Cormorant Global Healthcare Master Fund, LP (1,190,855 shares), LBC Sunshine Healthcare Fund L.P. (4,000,000 shares), Link Spirit Holdings Limited (1,714,280 shares), TK Derma Limited (8,571,430 shares), CICC GF No. 1 Limited (4,571,430 shares), C&D No. 7 Holdings Limited (4,000,000 shares), Fidelity China Special Situations PLC (5,387,295 shares), Fidelity Funds (16,749,245 shares), Fidelity Investment Funds (592,455 shares ), United Strength Neptune Limited (4,924,615 shares), Goldstream Capital Segregated Portfolio Company ? Goldstream Healthcare Focus Fund SP (757,635 shares), have agreed for the lock-up of six month period ending on December 11, 2023.